Q32 Bio Inc. and Homology Medicines, Inc. have agreed to a definitive merger agreement in an all-stock transaction. The consolidated company will keep the Q32 Bio Inc. name and be headquartered in Waltham, Massachusetts. Q32 has also regained all rights from Amgen for bempikibart, a drug in Phase 2 trials for treating autoimmune diseases atopic dermatitis and alopecia areata. Concurrently, Q32 Bio agreed to a $42 million private investment to support clinical development.
How the explosion in machine identities is changing cyber defense
The rapid adoption of machine identities such as AI agents is creating new vulnerabilities and fresh challenges for IT teams
